Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 20/20 | 0.75 |
| ▸ | HTR1D | P28221 | 20/20 | 0.75 |
| ▸ | HTR1B | P28222 | 19/20 | 0.75 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.75 |
| ▸ | DRD2 | P14416 | 1/20 | 0.75 |
| ▸ | HTR2A | P28223 | 1/20 | 0.75 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.75 |
| ▸ | HTR7 | P34969 | 1/20 | 0.75 |
| ▸ | DRD3 | P35462 | 1/20 | 0.75 |
| ▸ | HTR2B | P41595 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5371549 | 0.89 | HTR1D (0.74) | HTR1AHTR1DHTR1BADRB1DRD2 | |
| SCHEMBL5364247 | 0.86 | HTR1A (1.00) | HTR1AHTR1DHTR1BADRB1DRD2 | |
| SCHEMBL29388787 | 0.86 | HTR1A (1.00) | HTR1AHTR1DHTR1BADRB1DRD2 | |
| SCHEMBL29462269 | 0.82 | HTR1D (0.93) | HTR1AHTR1DHTR1BADRB1DRD2 | |
| SCHEMBL5364221 | 0.82 | HTR1A (0.72) | HTR1AHTR1DHTR1BADRB1DRD2 | |
| SCHEMBL14565038 | 0.80 | HTR1A (1.00) | HTR1AHTR1DHTR1BADRB1DRD2 | |
| SCHEMBL5369349 | 0.80 | HTR1A (0.76) | HTR1AHTR1DHTR1BADRB1DRD2 | |
| SCHEMBL6398686 | 0.80 | HTR1A (1.00) | HTR1AHTR1DHTR1BDRD2HTR2A | |
| SCHEMBL5206749 | 0.80 | HTR1A (0.80) | HTR1AHTR1DHTR1BDRD2HTR2A | |
| SCHEMBL6392503 | 0.79 | HTR1A (0.76) | HTR1AHTR1DHTR1BDRD2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7244726-B2 | Heterocyclic compounds possessing affinity at 5HT1 -type receptors and use thereof in therapy | GLAXO GROUP LIMITED (GB) | 2007-07-17 | — | — | US | claimed |
| EP-1755610-A2 | THIENOPYRIMIDINES AND THIAZOLOPYRIMIDINES FOR USE IN MEDICINE | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | claimed |
| EP-1476444-B1 | HETEROCYCLIC COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2006-04-12 | — | — | EP | claimed |
| WO-2005117890-A2 | THIENOPYRIMIDINES AND THIAZOLOPYRIMIDINES FOR USE IN MEDICINE | ASTRAZENECA AB (SE) | 2005-12-15 | — | — | WO | claimed |
| US-20050085458-A1 | Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy | GLAXO GROUP LIMITED (GB) | 2005-04-21 | — | — | US | claimed |
| EP-1476444-A1 | HETEROCYCLIC COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2004-11-17 | — | — | EP | claimed |
| WO-2003068772-A1 | HETEROCYCLIC COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | claimed |
| US-7244726-B2 | Heterocyclic compounds possessing affinity at 5HT1 -type receptors and use thereof in therapy | GLAXO GROUP LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| EP-1476444-B1 | HETEROCYCLIC COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY | GLAXO GROUP LTD (GB) | 2006-04-12 | — | — | EP | disclosed |
| US-20050085458-A1 | Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy | GLAXO GROUP LIMITED (GB) | 2005-04-21 | — | — | US | disclosed |
| EP-1476444-A1 | HETEROCYCLIC COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2004-11-17 | — | — | EP | disclosed |
| WO-2003068772-A1 | HETEROCYCLIC COMPOUNDS POSSESSING AFFINITY AT 5HT1-TYPE RECEPTORS AND USE THEREOF IN THERAPY | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085458-A1 | Heterocyclic compounds possessing affinity at 5ht1-type receptors and use thereof in therapy | HTR3C, HTR1A, HTR2C | HTR1A 2/4885HTR1D 4/4885HTR1B 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.